Isoquercetin

Isoquercetin

SCHEMBL181306

O=c1c(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)c(O)c2)oc2cc(O)cc(O)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
P4HB P07237 6/20 1.00
KDM4E B2RXH2 5/20 1.00
AKR1B1 P15121 5/20 1.00
EPHX2 P34913 5/20 1.00
GAA P10253 4/20 1.00
POLB P06746 3/20 1.00
MAPT P10636 3/20 1.00
CA12 O43570 3/20 1.00
CA2 P00918 3/20 1.00
CA4 P22748 3/20 1.00
CA7 P43166 3/20 1.00
ALPL P05186 2/20 1.00
ALPI P09923 2/20 1.00
SLCO2B1 O94956 2/20 1.00
MAOA P21397 2/20 1.00
XDH P47989 2/20 1.00
ADRA2C P18825 1/20 1.00
NOX4 Q9NPH5 1/20 1.00
KDM1A O60341 1/20 1.00
HMGB1 P09429 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Isoquercetin SCHEMBL15147267 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL2286562 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL12710506 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL6849311 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL561412 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL24609 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL19214052 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL21244358 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL22495101 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA
Isoquercetin SCHEMBL672012 1.00 P4HB (1.00) P4HBKDM4EAKR1B1EPHX2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 406 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250281451-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF BRIGHTSEED, INC. 2025-09-11 US claimed
WO-2024112947-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF BRIGHTSEED, INC. (US) 2024-05-30 WO claimed
US-11739113-B2 Method for extracting and separating flavonoids from Lindera aggregata leaves Ningbo Municipal Hospital of T.C.M. (CN) 2023-08-29 US claimed
US-20230147050-A1 Method For Extracting And Separating Flavonoids From Lindera Aggregata Leaves Ningbo Municipal Hospital of T.C.M. (CN) 2023-05-11 US claimed
EP-4144217-A1 ANTIMICROBIAL COMPOSITION FOR HARD SURFACES Viraschutz Europe S.r.l. (IT) 2023-03-08 EP claimed
US-20220098418-A1 CURABLE COATING COMPOSITIONS AND ANTIMICROBIAL COATINGS MADE BY CURING SUCH COATING COMPOSITIONS GREEN THEME TECHNOLOGIES, INC. 2022-03-31 US claimed
CN-110615821-A Mulberry extract, extraction and separation method and application thereof 西北大学 2019-12-27 CN claimed
CN-106046081-B The preparation and application of flavonoid glycoside active component in a kind of polygonum capitatum 浙江大学 2019-05-21 CN claimed
US-9381223-B2 Methods for inhibiting advanced glycation end product production, inhibiting fibroblast apoptosis, and/or promoting human fibroblast-collagen grating formulation using cherry blossom and cherry leaf extract ORYZA OIL & FAT CHEMICAL CO., LTD. (JP) 2016-07-05 US claimed
US-20150190369-A1 QUERCETIN-3-GLUCOSIDE AND USES THEREOF MBIKAY MAJAMBU (CA) 2015-07-09 US claimed
WO-2008032105-A2 FLAVONOID DERIVATIVES AND THEIR USES THE BABRAHAM INSTITUTE (GB) 2008-03-20 WO claimed
EP-1814559-A1 METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2007-08-08 EP claimed
CN-1978452-A New process for preparing isoquercitrin UNIV XINJIANG MEDICAL (CN) 2007-06-13 CN claimed
WO-2006090206-A1 IMPROVED EXTRACTS OF PSIDIUM GUAJAVA L., METHODS FOR ITS OBTAINING AND USE FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS LOZOYA LEGORRETA XAVIER (MX) 2006-08-31 WO claimed
WO-2006045050-A1 METHODS AND COMPOSITIONS FOR PROTECTING CELLS FROM ULTRASOUND-MEDIATED CYTOLYSIS THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, NATIONAL INSTITUTES OF HEALTH (US) 2006-04-27 WO claimed
EP-1649761-A1 Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-04-26 EP claimed
EP-1300084-B1 Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves BOEHRINGER INGELHEIM INT (DE) 2006-04-19 EP claimed
EP-1300084-A2 Composition for the treatment of chronic venous insufficiencies comprising an extract of red vine leaves BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 2003-04-09 EP claimed
EP-1225810-B1 METHOD FOR TREATMENT OF CHRONIC VENOUS INSUFFICIENCIES USING AN EXTRACT OF RED VINE LEAVES BOEHRINGER INGELHEIM INT (DE) 2003-03-26 EP claimed
WO-2001003687-A2 METHOD AND COMPOSITIONS FOR INHIBITING BIOSYNTHESIS OR BIOACTIVITY OF ENDOGENOUS STEROID SEX HORMONES IN HUMANS CEDARS-SINAI MEDICAL CENTER (US) 2001-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250281451-A1 COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND USES THEREOF PER2, PYGB, CRY2 P4HB 4412/4885KDM4E 256/4885AKR1B1 4602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.